RT Journal Article
SR Electronic
T1 A Breast Cancer Polygenic Risk Score Validation in 15,490 Brazilians using Exome Sequencing
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.04.21.24306089
DO 10.1101/2024.04.21.24306089
A1 Rius, Flávia Eichemberger
A1 Guindalini, Rodrigo
A1 Viana, Danilo
A1 Salomão, Júlia
A1 Gallo, Laila
A1 Freitas, Renata
A1 Bertolacini, Cláudia
A1 Taniguti, Lucas
A1 Imparato, Danilo
A1 Antunes, Flávia
A1 Sousa, Gabriel
A1 Achjian, Renan
A1 Fukuyama, Eric
A1 Gregório, Cleandra
A1 Ventura, Iuri
A1 Gomes, Juliana
A1 Taniguti, Nathália
A1 Maistro, Simone
A1 Krieger, José Eduardo
A1 Zheng, Yonglan
A1 Huo, Dezheng
A1 Olopade, Olufunmilayo I.
A1 Koike, Maria Aparecida
A1 Schlesinger, David
YR 2024
UL http://medrxiv.org/content/early/2024/04/22/2024.04.21.24306089.abstract
AB Purpose Brazil has a highly admixed population. Polygenic Risk Scores (PRS) have been mostly developed from European population studies and applying them to other populations is challenging. To assess the use of PRS for breast cancer (BC) risk in Brazil, we validated four PRSs developed in the Brazilian population.Patients and Methods We analyzed 6,362 women with a history of breast cancer and 9,128 unphenotyped adults as controls in a sample obtained from a clinical laboratory. Genomic variants were imputed from exomes and scores were calculated for all samples.Results After excluding individuals with known pathogenic or likely pathogenic variants in BRCA1, BRCA2, PALB2, PTEN, or TP53, and first-degree relatives of the probands, 5,730 cases and 8,847 controls remained. Four PRS models were compared, and PRS 3820 from Mavaddat et al. 2019 performed best, with an Odds Ratio (OR) of 1.41 per standard deviation (SD) increase (p-value: < 0.0001) and an OR of 1.94 (p-value: < 0.0001) for the individuals in the top risk decile. PRS 3820 also performed well for different ancestry groups: East Asian majority (Group 1), Non-European majority (Group 2), and European majority (Group 3), showing significant effect sizes for all groups: (Group 1: OR 1.54, p-value 0.006; Group 2: OR 1.44, p-value: <0.001; Group 3 OR: 1.43, p-value: <0.001). PRS 90% compares with monogenic moderate BC risk genes (PRS90 OR: 1.94; CHEK2 OR: 1.89; ATM OR: 1.99).Conclusion PRS 3820 can be accurately used in the Brazilian population. This will allow a more precise BC risk assessment of mutation-negative women in Brazil.Competing Interest StatementFlávia Eichemberger Rius, Danilo Viana, Júlia Salomão, Laila Gallo, Renata Freitas, Cláudia Bertolacini, Lucas Taniguti, Danilo Imparato, Flávia Antunes, Gabriel Sousa, Renan Achjian, Eric Fukuyama, Cleandra Gregório, Iuri Ventura, Juliana Gomes, Nathália Taniguti, and David Schlesinger are currently employed by Mendelics, or were employed at the time of the study. Rodrigo Guindalini acted as a consultant for AstraZeneca, Janssen Oncology, Roche/Genentech and Igenomix; received speaker honoraria from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Merck Sharpe & Dohme Brasil, Novartis, and Roche outside the submitted work; and has equity in Mendelics Análise Genômica. Olufunmilayo I. Olopade is co-founder at CancerIQ; serves as scientific advisor at Tempus; and has received research funding from Color Genomics and Roche/Genentech. José Eduardo Krieger, Yonglan Zheng, Dezheng Huo, Simone Maistro and Maria Aparecida Koike declare no competing interests. Funding StatementMaria Aparecida Azevedo Koike Folgueira received research support from Conselho Nacional de Desenvolvimento Científico e Tecnológico, Brazil (CNPq-308052/2022-6). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was approved by the Ethics Committee Comissão para análise de projeto de pesquisa of Hospital das Clínicas da FMUSP - CAPPesq under the CAAE number 70112423.3.0000.0068I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript or in the Supplementary Material. Individual cases and controls data are not publicly available due to the confidentiality consentment agreement signed by all included in the study.All variants and betas which compose the four evaluated PRSs are available as Supplementary Information. Individual cases and controls data are not publicly available due to the confidentiality consentment agreement signed by all included in the study.